Legacy Health System

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 4 drugs with upcoming expirations

Activity

Key Events

Aug 27, 2026TrialEffects of Hyperbaric Oxygen Therapy on Glucose Homeostasis in Patients Living With Diabetes Mellitus

Feb 10, 2026TrialImpact of Daridorexant on Sleep, Daytime Alertness, and Smoking

Dec 12, 2024FDAZanaflex — ONTRALFY

Nov 22, 2024FDAZanaflex — ZANAFLEX

May 31, 2024FDAZanaflex — ZANAFLEX

Sep 8, 2023FDALotronex — LOTRONEX

Jan 7, 2021TrialSupracondylar Pinning Antibiotic Stewardship (SPAS) Trial

4 more events

Dec 18, 2020FDAZanaflex — ZANAFLEX

May 27, 2020FDAZanaflex — TIZANIDINE HYDROCHLORIDE

Jul 1, 2019TrialAcute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy

May 23, 2019TrialSafety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

14 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Esbriet3 patentsSep 22, 2026 Esbriet3 patentsDec 18, 2027 EsbrietMay 10, 2028 BetapaceAug 14, 2028 Esbriet4 patentsApr 22, 2029 Esbriet7 patentsJan 8, 2030 Naftin6 patentsJan 31, 2033 EsbrietAug 30, 2033

6 more

Betapace4 patentsApr 1, 2034 BetapaceAug 31, 2035 EsbrietMar 28, 2037 Betapace3 patentsAug 14, 2038 Betapace3 patentsApr 5, 2039 Zanaflex2 patentsMay 7, 2042

Regulatory

Regulatory Timeline

20131 event

FDANov 7

Zanaflex — ZANAFLEX

Application NDA021447

20145 events

FDAOct 22

Betapace — SOTYLIZE

Application NDA205108 (NDA)

FDAOct 15

Esbriet — ESBRIET

Application NDA022535 (NDA)

FDAOct 15

Esbriet — ESBRIET

Application NDA022535 (NDA)

FDAAug 29

Zanaflex — ZANAFLEX

Application NDA021447

FDAMay 8

Lotronex — LOTRONEX

Application NDA021107

20151 event

FDAJul 24

Lotronex — LOTRONEX

Application NDA021107

20163 events

FDAMay 27

Zanaflex — ZANAFLEX

Application NDA020397

FDAJan 7

Lotronex — LOTRONEX

Application NDA021107

FDAJan 7

Lotronex — LOTRONEX

Application NDA021107

20172 events

FDAJan 11

Esbriet — ESBRIET

Application NDA208780 (NDA)

FDAJan 11

Esbriet — ESBRIET

Application NDA208780 (NDA)

20191 event

FDAApr 3

Lotronex — LOTRONEX

Application NDA021107

20202 events

FDADec 18

Zanaflex — ZANAFLEX

Application NDA021447

FDAMay 27

Zanaflex — TIZANIDINE HYDROCHLORIDE

Application ANDA213798

20231 event

FDASep 8

Lotronex — LOTRONEX

Application NDA021107

20244 events

FDADec 12

Zanaflex — ONTRALFY

Application NDA216190 (NDA)

FDANov 22

Zanaflex — ZANAFLEX

Application NDA020397

FDANov 22

Zanaflex — ZANAFLEX

Application NDA021447

FDAMay 31

Zanaflex — ZANAFLEX

Application NDA020397

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)